Cash Flow Strengthens Despite Top-Line Headwinds
Cross Country Healthcare's latest quarterly report for Q3 2025 reveals a business weathering transition and external pressures, with its robust operational cash flow and balance sheet standing out amid declining revenues and profitability. While overall revenue dropped 21% year-over-year to $250.1 million, the company generated a solid $20.1 million in cash from operations this quarter—a 169% jump from last year and a nearly five-fold increase over the previous quarter. As of September 30, Cross Country reported $99.1 million in cash and no debt, offering significant financial flexibility as the company awaits resolution of its pending merger with Aya Healthcare.
| Key Metric | Q3 2025 | Q2 2025 | Q3 2024 | % YoY Change |
|---|---|---|---|---|
| Revenue | $250.1M | $274.1M | $315.1M | -21% |
| Gross Profit Margin | 20.4% | 20.4% | 20.4% | Unchanged |
| Adjusted EBITDA | $6.52M | $7.59M | $10.34M | -37% |
| Net Cash from Operations | $20.1M | $4.22M | $7.47M | +169% |
| Cash & Equivalents (End of Period) | $99.1M | $81.2M | $64.0M | +55% |
| Debt | $0 | $0 | $0 | -- |
Homecare Staffing Momentum Counters Revenue Pressure
Despite headwinds across the broader staffing industry, Cross Country posted more than 29% growth in homecare staffing revenue versus the prior year. This strong performance, alongside sequential declines in selling, general, and administrative expenses, helped stabilize profitability in a tough operating environment. In the company’s core Nurse and Allied Staffing segment, contribution income ticked up slightly from the prior quarter, indicating efficiency improvements. Meanwhile, revenue per field contract personnel per day dipped modestly to $343 from $348 in Q2, with average FTEs declining to 6,371.
| Business Segment | Q3 2025 Revenue | % Change YoY | Q3 2025 Contribution Income |
|---|---|---|---|
| Nurse & Allied Staffing | $202.0M | -24% | $14.23M |
| Physician Staffing | $48.1M | -4% | $4.32M |
Balance Sheet Remains Healthy with Ample Liquidity
The company exited the quarter with $99.1 million in cash, $103 million in net borrowing base availability on its credit facility, and no outstanding debt. This liquidity position allows Cross Country to keep investing in its proprietary tech platforms, such as Intellify and xPerience, and positions the company well whether the Aya merger closes or not. No share repurchases were made during the quarter, with $40.5 million still authorized for future buybacks.
Aya Merger Update: Timeline Remains Uncertain
One of the most significant near-term variables for Cross Country is the status of its merger with Aya Healthcare. Although stockholder approval has been secured, the merger’s closing remains in limbo due to the ongoing FTC review, further delayed by the government shutdown. If the transaction does not close by December 3, 2025, either party may walk away, and there is no guarantee the deal will be extended. Completion would mean Cross Country becomes private, ceasing trading on Nasdaq.
Profitability Pressures Tempered by Cost Management and Segment Performance
Net loss for the quarter was $4.77 million compared to a $2.56 million profit a year ago, though improved sequentially from a $6.66 million loss last quarter. Adjusted EBITDA margin narrowed to 2.6% from 3.3% last year, as a mix of lower revenues and restructuring costs took hold. However, SG&A efficiencies from its India-based center of excellence and investments in digital capabilities offer evidence of strategic cost control and forward-thinking.
Takeaway: Liquidity and Operational Focus Provide Cushion Amid Merger and Market Uncertainty
With strong cash flow, zero debt, and momentum in homecare staffing, Cross Country Healthcare is well-positioned to manage ongoing challenges and the unresolved Aya Healthcare merger. Investors should watch for further developments on the regulatory front, as the timing and outcome of the merger remain a wildcard. Meanwhile, the company's solid liquidity, focus on technology, and effective cost management could help cushion near-term earnings volatility and sustain operational flexibility—regardless of how the merger plays out.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI